In 2007, there was HIV trials using an adenovirus 5 that raised concern of the infection.

And this was in science, yeah, in science mag. There was a headline here we have this.

Could, yeah, could certain COVID-19 vaccines lead people more vulnerable to the AIDS virus?

Now, they were using adenovirus 5 as the vector.

So what they do is the vector is how I was explained to me or through my research is

like the spaceship that carries the spike protein and the viral parts into the cell or onto the cell that attaches.

So in sub-Saharan Africa, AD5, the adenovirus 5 is very prominent.

So people had immunity to that, natural immunity to that already.

So when they came in with this vaccine that used that vector, they were finding that men,

males were becoming more susceptible to HIV during a vaccine trials that were trying to

prevent HIV. So that became a big problem.

And that again was Fauci, right? That's Fauci. I think Deborah Berks is in there on the HIV vaccine.

Never came about. They ended up causing HIV with the vaccine, which is obviously not the desired effect.

And when you mention adenovirus and immunity in Africa, I mean, if that is the vessel that's delivering, you know,

the particles that you need to get to the cell to create immunity, what if the body's already immune to it?

That means you have antibodies that are going to attack that adenovirus, which is there to protect what's inside of it.

But if your body attacks it, wouldn't it stand a reason that the particles will never get to the cell because our bodies are reaching out?

And if we're already immune to adenovirus, we could just attack that adenovirus and will never make its journey to ourselves.

Correct. Correct. And this is called anti-vector immune response.

And this is an issue in AstraZeneca actually used a chimp adenovirus to avoid this whole issue of a prior immunity.

And with Johnson and Johnson, we have an article here. It's about that anti-vector immunity.

So it's called adenovirus vector COVID-19 vaccines efficacy during a potential re-vaccination campaign likely to be stifled by anti-vector response.

...